Brief: Biocryst Completes Sale Of European Orladeyo® (Berotralstat) Business
01/10/2025 12:22
Oct 1 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST COMPLETES SALE OF EUROPEAN ORLADEYO® (BEROTRALSTAT) BUSINESS Source text: ID:nGNXb6rm4l Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026